Search Results
Your search for The ASCO matches 21410 pages
Showing 5451 - 5500
David S. Kroll, MD, on Recognizing and Treating Depression and Anxiety in Patients With Lymphoma
David S. Kroll, MD, of Brigham and Women’s Hospital, discusses the symptoms of distress in patients with lymphoma and other oncologic malignancies, risk factors for poor outcomes, and how best to approach the management of depression and anxiety in this population.
Peihua (Peggy) Lu, MD, on CAR T-Cell Therapy: Research in China
Peihua Lu, MD, of Lu Daopei Hospital, discusses the state of research in China on CAR T-cell therapy, placing it in the context of the global development pipeline and the progress being made.
Outcomes and Behaviors Among Women Receiving or Declining Their Breast Cancer Polygenic Risk Score
A recent study examined patient-reported outcomes and risk-management behaviors of women choosing to receive or decline their breast cancer polygenic risk scores (PRS). The findings were published by Tatiane Yanes, PhD, and colleagues in Genetics in Medicine. The research aimed to look at how the...
Enrollment of AYA Patients Into NCI-Sponsored Clinical Trials: 25-Year Analysis
Adolescent and young adult (AYA) patients with cancer have not seen the same improvements in survival over the years as their pediatric and older adult counterparts. Some evidence has suggested that this may in part be a result of low AYA participation in clinical trials, limiting advances in...
Association of Incomplete Polyp Removal With Risk of Postcolonoscopy Colorectal Cancer
A multicenter cohort study found that incomplete polyp removal—polyp removal where neoplastic tissue is found in any of the marginal biopsies—is a likely contributor to neoplasia recurrence and interval colorectal cancer. The results highlight the critical importance of polyp resection technique in ...
Olufunmilayo Olopade, MD, FAACR, to Receive SABCS 2021 William L. McGuire Memorial Lecture Award
Olufunmilayo Olopade, MD, FAACR, will receive the William L. McGuire Memorial Lecture Award at the 2021 San Antonio Breast Cancer Symposium (SABCS), to be held December 7–10. The McGuire Award was established in 1992 to commemorate the significant contributions to breast oncology by Dr. McGuire...
Conquer Cancer Announces 2021 Israel Cancer Research Fund Career Development Award
Conquer Cancer, the ASCO Foundation, is pleased to announce Shlomit Strulov Shachar, MD, of Tel Aviv Sourasky Medical Center, is the recipient of the 2021 Conquer Cancer–Israel Cancer Research Fund (ICRF) Career Development Award. Dr. Shachar’s proposed study, entitled “Identifying Molecular...
ASCO and Community Oncology Alliance Publish Standards for Oncology Medical Home Model
ASCO and the Community Oncology Alliance (COA) have published standards for the oncology medical home (OMH), a comprehensive system of care delivery that supports coordinated, efficient, accessible, and evidence-based care.1 The standards serve as a roadmap for practice...
Oncology Practices Nationwide Show High Interest in Diversifying Cancer Clinical Trials
ASCO and the Association of Community Cancer Centers (ACCC) recently announced that 75 research sites applied and have been invited to participate in a pilot project testing a research site self-assessment tool and an implicit bias training program focused on increasing racial and ethnic diversity...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bahrain
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Bahrain. The aim of this special feature is to highlight the global cancer burden for various countries of the...
The Patient We See and the Person We May Not
A middle-aged patient was referred to our clinic with a mass in his liver. It had been detected the preceding year, and the patient underwent a battery of investigations with scans and biopsies to reach a diagnosis of metastatic lesion of the liver. After appropriate consultations with oncologists, ...
Fred Hutchinson Cancer Research Center, Seattle Children’s, and UW Medicine Lay Groundwork for Cancer Partnership
Fred Hutchinson Cancer Research Center (Fred Hutch), University of Washington (UW) Medicine, Seattle Cancer Care Alliance (SCCA), and Seattle Children’s have announced plans to explore restructuring their longtime relationship to accelerate a shared mission of advancing diagnosis, treatment, and...
JAVELIN Head and Neck 100 Trial: When Failure Seems Fatal, Hope Is Not Lost
Data from KEYNOTE-048 showed that the combination of the checkpoint inhibitor pembrolizumab with platinum-containing therapy improved overall survival vs cetuximab plus chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).1 The findings provided hope...
Salvage and Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: What’s ‘Just Right’ for Our Patients?
In the storied English fable “Goldilocks and the Three Bears,” a child enters a home and tastes three bowls of porridge. She prefers a bowl that is not too cold and not too hot but one that has just the right temperature. This “Goldilocks principle” of “just the right amount” can be applied to the...
NCCN Foundation Announces Awards for Rising Cancer Research Leaders
The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® have announced six new recipients for the 2021 NCCN Foundation Young Investigator Awards Program. The honorees will receive up to $150,000 in funding in the course of 2 years to advance research on important issues in...
Expert Point of View: Nicole Chau, MD
ASCO discussant Nicole Chau, MD, Clinical Associate Professor at the University of British Columbia/BC Cancer in Vancouver, said the COSMIC-311 trial was “noteworthy for meeting its co-primary endpoint of progression-free survival (hazard ratio = 0.22) in this heavily pretreated patient...
Cabozantinib: Potential New Option for Treatment-Refractory Thyroid Cancer
The tyrosine kinase inhibitor cabozantinib appears to be an effective new option for treatment-refractory differentiated thyroid cancer, according to the phase III COSMIC-311 trial, which was stopped early for efficacy.1 COSMIC-311 is the first randomized placebo-controlled trial to evaluate the...
Expert Point of View: Melinda L. Telli, MD
The invited discussant of GeparNuevo,1 Melinda L. Telli, MD, Associate Professor of Medicine at Stanford University School of Medicine, Director of the Breast Cancer Program at the Stanford Cancer Institute, and Associate Director of the Stanford Women’s Cancer Center, welcomed the additional data...
Neoadjuvant Durvalumab Improves Long-Term Outcomes in the GeparNuevo Trial
In the phase II GeparNuevo trial, patients with early triple-negative breast cancer receiving the PD-L1 inhibitor durvalumab in addition to chemotherapy as neoadjuvant therapy saw improvements in long-term outcomes. The results were presented at the 2021 ASCO Annual Meeting by Sibylle Loibl, MD,...
Expert Point of View: Jacqueline C. Barrientos, MD, MS
The ASCO Post invited Jacqueline C. Barrientos, MD, MS, Associate Professor of Medicine, CLL Research and Treatment Program, Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, to comment on the ALPINE findings presented at the European Hematology Association (EHA) Virtual...
Zanubrutinib Superior to Ibrutinib for CLL/SLL in Phase III ALPINE Trial
Zanubrutinib, a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, significantly improved response rates and delayed disease progression as compared with the standard of care, ibrutinib, in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma...
Expert Point of View: Kei Muro, MD, PhD
The RATIONALE 302 trial1 was discussed by Kei Muro, MD, PhD, of Aichi Cancer Center Hospital in Nagoya, Japan, who found the results promising. However, Dr. Muro questioned the role of PD-1/L1 inhibitors as second-line therapy for advanced esophageal squamous cell carcinoma. RATIONALE 302 is the...
Expert Point of View: Thomas Seufferlein, MD, PhD
The invited discussant of APACT,1 Thomas Seufferlein, MD, PhD, Professor of Medicine at the University of Ulm in Germany, said the updated overall survival data “suggest an improved outcome with nab-paclitaxel plus gemcitabine vs gemcitabine alone…. The combination improves long-term survival and...
APACT: 5-Year Overall Survival Data Suggest Improved Outcomes in Pancreatic Cancer With Nab-paclitaxel/Gemcitabine
The 5-year outcomes in the APACT trial uphold the overall survival benefit with nab-paclitaxel plus gemcitabine in the adjuvant treatment of patients with resected pancreatic cancer, according to Margaret A. Tempero, MD, Director of the University of California San Francisco Pancreas Center, who...
2021 ASCO Annual Meeting: Next-Generation Oncology Highlights
The 2021 ASCO Annual Meeting was presented totally virtually again due to the persistence of the COVID-19 pandemic. Nevertheless, the meeting held widespread interest, and we were able to attend an event with important changes for the practice of oncology. Compared with 2020, fewer “next-generation ...
Study Investigates Relationship Between Peanut Agglutinin and Cancer Metastasis
A study published by Wang et al in the journal Carcinogenesis has identified new factors accompanying previous findings that frequent consumption of peanuts by patients with cancer could increase the risk of metastasis. Relationship Examined The results show that peanut agglutinin—a...
Disparities Observed in Follow-up Care Among Young Adult Childhood Cancer Survivors
A research team examined gaps and disparities in lifelong follow-up among childhood cancer survivors, including taking a closer look at long-term follow-up care plans, specifically for underserved populations. Their study showed that age and ethnic background are associated with inadequate...
Study Finds COVID-19 Vaccine Is Safe in Patients With Hematologic Malignancies, but 25% of These Patients Do Not Produce Detectable Antibodies
About one in four patients with blood cancer fail to produce detectable antibodies after COVID-19 vaccination, but results vary substantially by type of blood cancer, according to a study by Greenberger et al published in the journal Cancer Cell. Although earlier studies have shown that certain...
Radiation Oncologists Urge Congress to Create More Equity in Access to Care
A record number of radiation oncologists met with Congressional leaders and staff in July as part of the largest American Society for Radiation Oncology (ASTRO) Advocacy Day in the Society’s history, according to a news release from ASTRO. The physicians urged Congressional leaders to intervene in...
Facing the Trauma of Colorectal Cancer
I first noticed blood in my stool when I was in the 8th grade. My mom and I did an Internet search and were relieved to find that the cause was most likely nothing more serious than hemorrhoids, so I put the problem out of my mind. I played volleyball and had an active social life, and the...
AMA, Satcher Health Leadership Institute Announce Inaugural Recipients of Health Equity Advocacy Fellowship
The American Medical Association (AMA) and the Satcher Health Leadership Institute at the Morehouse School of Medicine recently announced the selection of 12 physicians as the inaugural group of fellows for the Medical Justice in Advocacy Fellowship. This new collaborative initiative is intended to ...
AACI Members Choose Robert Winn, MD, as Vice President/President-Elect, and Other New Leaders
Robert Winn, MD, Director of Virginia Commonwealth University (VCU) Massey Cancer Center, has been elected by the members of the Association of American Cancer Institutes (AACI) to serve as Vice President/President-Elect of AACI’s Board of Directors. Dr. Winn’s new position is effective...
2021 ASCO Annual Meeting: Next-Generation Oncology Highlights
The 2021 ASCO Annual Meeting was presented totally virtually again due to the persistence of the COVID-19 pandemic. Nevertheless, the meeting held widespread interest, and we were able to attend an event with important changes for the practice of oncology. Compared with 2020, fewer...
Nationally Recognized Biostatistician Joins Rutgers to Focus on Cancer Research
The Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey have welcomed nationally recognized biostatistician Hao Liu, PhD. Dr. Liu will serve as Professor in the Department of Biostatistics and Epidemiology at Rutgers School of Public Health, Director of the Biostatistics...
Mount Sinai Welcomes Robotic Prostate Surgery Pioneer Mani Menon, MD
Robotic prostate surgery pioneer Mani Menon, MD, is joining Mount Sinai and will serve as Chief of Strategy and Innovation in the Department of Urology for the Mount Sinai Health System. He will also serve as Professor of Urology, Director of Education, and Director of the Precision Prostatectomy...
Roswell Park Approved to Provide Care for World Trade Center 9/11 First Responders
Nearly 20 years ago, first responders from across New York State answered the call for help when thousands of people were injured or killed in the terrorist attacks of September 11, 2001. A new program at Roswell Park Comprehensive Cancer Center will ensure that these police officers, firefighters, ...
From Istanbul to Orange County, an Oncologist’s Journey to a Leadership Role in Quality Care
Pelin Cinar, MD, MS, was born and reared in Istanbul, Turkey. “My father ran a small furniture business, and my mother was a homemaker. However, I had a distant cousin who was an obstetrician-gynecologist, but he did house calls and treated any number of health issues in the community. Early on, I ...
CAR T-Cell Gene Therapy in Non-Hodgkin Lymphomas
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel gene therapies for resistant non-Hodgkin lymphomas (NHL), including...
A New Era of Hope for Patients With Triple-Negative Breast Cancer
Triple-negative breast cancer is a particularly devastating subtype of breast cancer, as it is often diagnosed in young women and is associated with an exceptionally poor prognosis. The “triple-negative” designation indicates that the three key features driving most breast cancers (estrogen...
Is Disease-Free Survival the Best Endpoint for Adjuvant Nivolumab in High-Risk, Muscle-Invasive Urothelial Carcinoma?
The role of adjuvant treatment for invasive, high-grade bladder cancer remains controversial and challenging. Sternberg et al reported a statistically significant progression-free survival benefit from adjuvant combination gemcitabine/cisplatin (GC) or MVAC (methotrexate, vinblastine, doxorubicin, ...
Cutaneous HPV May Be a Predictor of Cutaneous Squamous Cell Carcinoma Risk
In an article published by Rollison et al in Cancer Research, researchers demonstrated a link between the presence of cutaneous human papillomavirus (HPV) and the incidence of cutaneous squamous cell carcinomas. They also identified key characteristics of infection that may contribute to...
Lung Cancer Screening Rates Improved in 19 States Despite the COVID-19 Pandemic
A new population-based study showed that although national lung cancer screening rates decreased in some states, 19 states actually experienced significant improvements in screening rates despite the COVID-19 pandemic. Overall lung cancer screening rates remained low and unchanged, according to...
An Egyptian Surgical Oncologist Urges Global Cooperation to Achieve Equitable Cancer Care
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Ashraf Zaghloul, MD, DrPH, Professor at the National Cancer Institute of Egypt and President of the Egyptian Society of Surgical Oncology. Dr. Zaghloul was born in 1956 in ...
Expert Point of View: Guru Subramanian Guru Murthy
Invited discussant Guru Subramanian Guru Murthy, MD, MS, of the Medical College of Wisconsin, Milwaukee, commented on the study of aspacytarabine in the first-line therapy for patients with acute myeloid leukemia (AML) unfit for standard chemotherapy. “This study elegantly highlights there is still ...
Study Finds Cytarabine Prodrug Active and Safe in Older Compromised Patients With AML
Aspacytarabine, a cytarabine prodrug, was reported to be safe and effective as first-line therapy for patients with acute myeloid leukemia (AML) who were unfit for intensive induction chemotherapy, according to the results of a phase II study presented during the 2021 ASCO Annual Meeting.1 The...
Use of Statins and Survival Outcomes Among Patients With Triple-Negative Breast Cancer
A study published by Nowakowska et al in the journal Cancer has found a significant association between the use of cholesterol-lowering statins and survival rates of patients with triple-negative breast cancer. Since statins are relatively inexpensive, easy to access, and produce minimal side...
Study Highlights Gaps in Mental Health and Chemical Dependency Care at U.S. Cancer Centers
Research published by Niazi et al in JNCCN—Journal of the National Comprehensive Cancer Network indicates a need to increase mental health and chemical dependency support capabilities at cancer centers across the United States. Previous studies have determined that people diagnosed with cancer...
Racial/Ethnic Disparities in Emergency Department Visits After Breast Cancer Surgery
Among women undergoing surgery for breast cancer, up to 13% will have a postoperative visit to an emergency department, according to recent research. A new study published by Falcone et al in Breast Cancer Research and Treatment discovered there is a greater likelihood that Hispanic and...
Neoadjuvant Cabozantinib/Nivolumab May Make Resection Possible for Some Patients With Liver Cancer
A combination of the kinase inhibitor cabozantinib and the immunotherapy nivolumab may make curative surgery possible for some patients with liver cancer who would generally not be considered candidates for surgery, according to research published by Ho et al in Nature Cancer. Rates of Resection...
Expert Point of View: Giuseppe Curigliano, MD, PhD
Invited discussant Giuseppe Curigliano, MD, PhD, Associate Professor of Medical Oncology at the University of Milan, Italy, and Head of the Division of Early Drug Development at the European Institute of Oncology, said the “clear” findings of KEYNOTE-5221 are “practice-changing.” However, the...
